Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin

被引:296
作者
Sasaki, T
Fukai, N
Mann, K
Göhring, W
Olsen, BR
Timpl, R [1 ]
机构
[1] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
关键词
binding properties; collagen; proteolysis; recombinant production; serum form;
D O I
10.1093/emboj/17.15.4249
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The C-terminal domain NC1 of mouse collagen XVIII (38 kDa) and the shorter mouse and human endostatins (22 kDa) were prepared in recombinant form from transfected mammalian cells. The NC1 domain aggregated non-covalently into a globular trimer which was partially cleaved by endogenous proteolysis into several monomers (25-32 kDa) related to endostatin. Endostatins were obtained in a highly soluble, monomeric form and showed a single N-terminal sequence which, together with other data, indicated a compact folding. Endostatins and NC1 showed a comparable binding activity for the microfibrillar fibulin-1 and fibulin-2, and for heparin. Domain NC1, however, was a distinctly stronger ligand than endostatin for sulfatides and the basement membrane proteins laminin-l and perlecan. Immunological assays demonstrated endostatin epitopes on several tissue components (22-38 kDa) and in serum (120-300 ng/ml), the latter representing the smaller variants. The data indicated that the NC1 domain consists of an N-terminal association region (similar to 50 residues), a central protease-sensitive hinge region (similar to 70 residues) and a C-terminal stable endostatin domain (similar to 180 residues). They also demonstrated that proteolytic release of endostatin can occur through several pathways, which may lead to a switch from a matrix-associated to a more soluble endocrine form.
引用
收藏
页码:4249 / 4256
页数:8
相关论文
共 44 条
[1]   IDENTIFICATION OF A NOVEL COLLAGEN CHAIN REPRESENTED BY EXTENSIVE INTERRUPTIONS IN THE TRIPLE-HELICAL REGION [J].
ABE, N ;
MURAGAKI, Y ;
YOSHIOKA, H ;
INOUE, H ;
NINOMIYA, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 196 (02) :576-582
[2]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[3]   Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth [J].
Cao, YH ;
Chen, A ;
An, SSA ;
Ji, RWD ;
Davidson, D ;
Cao, YM ;
Llinas, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (36) :22924-22928
[4]   Kringle domains of human angiostatin - Characterization of the anti-proliferative activity on endothelial cells [J].
Cao, YH ;
Ji, RW ;
Davidson, D ;
Schaller, J ;
Marti, D ;
Sohndel, S ;
McCance, SG ;
OReilly, MS ;
Llinas, M ;
Folkman, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) :29461-29467
[5]   THE 16-KILODALTON N-TERMINAL FRAGMENT OF HUMAN PROLACTIN IS A POTENT INHIBITOR OF ANGIOGENESIS [J].
CLAPP, C ;
MARTIAL, JA ;
GUZMAN, RC ;
RENTIERDELRUE, F ;
WEINER, RI .
ENDOCRINOLOGY, 1993, 133 (03) :1292-1299
[6]   Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides [J].
Costell, M ;
Mann, K ;
Yamada, Y ;
Timpl, R .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :115-121
[7]   CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells [J].
Dawson, DW ;
Pearce, SFA ;
Zhong, RQ ;
Silverstein, RL ;
Frazier, WA ;
Bouck, NP .
JOURNAL OF CELL BIOLOGY, 1997, 138 (03) :707-717
[8]   Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[9]   METHODS FOR INVESTIGATING THE ESSENTIAL GROUPS FOR ENZYME ACTIVITY [J].
FRAENKELCONRAT, H .
METHODS IN ENZYMOLOGY, 1957, 4 :247-269
[10]   DIFFERENTIAL-EFFECTS OF SPARC AND CATIONIC SPARC PEPTIDES ON DNA-SYNTHESIS BY ENDOTHELIAL-CELLS AND FIBROBLASTS [J].
FUNK, SE ;
SAGE, EH .
JOURNAL OF CELLULAR PHYSIOLOGY, 1993, 154 (01) :53-63